ter Haar, E. L. M. (2023) “Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks”, Acta Dermato-Venereologica, 103, p. adv17752. doi: 10.2340/actadv.v103.17752.